257 related articles for article (PubMed ID: 20530275)
1. Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials.
Russell SD; Blackwell KL; Lawrence J; Pippen JE; Roe MT; Wood F; Paton V; Holmgren E; Mahaffey KW
J Clin Oncol; 2010 Jul; 28(21):3416-21. PubMed ID: 20530275
[TBL] [Abstract][Full Text] [Related]
2. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.
Tan-Chiu E; Yothers G; Romond E; Geyer CE; Ewer M; Keefe D; Shannon RP; Swain SM; Brown A; Fehrenbacher L; Vogel VG; Seay TE; Rastogi P; Mamounas EP; Wolmark N; Bryant J
J Clin Oncol; 2005 Nov; 23(31):7811-9. PubMed ID: 16258083
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.
Baselga J; Perez EA; Pienkowski T; Bell R
Oncologist; 2006; 11 Suppl 1():4-12. PubMed ID: 16971734
[TBL] [Abstract][Full Text] [Related]
4. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility.
Telli ML; Hunt SA; Carlson RW; Guardino AE
J Clin Oncol; 2007 Aug; 25(23):3525-33. PubMed ID: 17687157
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant trastuzumab therapy for HER2-positive breast cancer.
Jahanzeb M
Clin Breast Cancer; 2008 Aug; 8(4):324-33. PubMed ID: 18757259
[TBL] [Abstract][Full Text] [Related]
6. Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial.
Perez EA; Suman VJ; Davidson NE; Kaufman PA; Martino S; Dakhil SR; Ingle JN; Rodeheffer RJ; Gersh BJ; Jaffe AS
J Clin Oncol; 2004 Sep; 22(18):3700-4. PubMed ID: 15365066
[TBL] [Abstract][Full Text] [Related]
7. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial.
Perez EA; Suman VJ; Davidson NE; Sledge GW; Kaufman PA; Hudis CA; Martino S; Gralow JR; Dakhil SR; Ingle JN; Winer EP; Gelmon KA; Gersh BJ; Jaffe AS; Rodeheffer RJ
J Clin Oncol; 2008 Mar; 26(8):1231-8. PubMed ID: 18250349
[TBL] [Abstract][Full Text] [Related]
8. Response and cardiac toxicity of trastuzumab given in conjunction with weekly paclitaxel after doxorubicin/cyclophosphamide.
Kelly H; Kimmick G; Dees EC; Collichio F; Gatti L; Sawyer L; Ivanova A; Dressler L; Graham ML; Carey LA
Clin Breast Cancer; 2006 Aug; 7(3):237-43. PubMed ID: 16942640
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Cardiac Safety Analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial.
Advani PP; Ballman KV; Dockter TJ; Colon-Otero G; Perez EA
J Clin Oncol; 2016 Feb; 34(6):581-7. PubMed ID: 26392097
[TBL] [Abstract][Full Text] [Related]
10. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer.
Romond EH; Jeong JH; Rastogi P; Swain SM; Geyer CE; Ewer MS; Rathi V; Fehrenbacher L; Brufsky A; Azar CA; Flynn PJ; Zapas JL; Polikoff J; Gross HM; Biggs DD; Atkins JN; Tan-Chiu E; Zheng P; Yothers G; Mamounas EP; Wolmark N
J Clin Oncol; 2012 Nov; 30(31):3792-9. PubMed ID: 22987084
[TBL] [Abstract][Full Text] [Related]
11. Safety of adjuvant trastuzumab for HER-2-overexpressing elderly breast cancer patients: a multicenter cohort study.
Sawaki M; Mukai H; Tokudome N; Nakayama T; Taira N; Mizuno T; Yamamoto Y; Horio A; Watanabe T; Uemura Y; Ohashi Y
Breast Cancer; 2012 Jul; 19(3):253-8. PubMed ID: 21526424
[TBL] [Abstract][Full Text] [Related]
12. Feasibility and cardiac safety of pegylated liposomal doxorubicin plus trastuzumab in heavily pretreated patients with recurrent HER2-overexpressing metastatic breast cancer.
Andreopoulou E; Gaiotti D; Kim E; Volm M; Oratz R; Freedberg R; Downey A; Vogel CL; Chia S; Muggia F
Clin Breast Cancer; 2007 Aug; 7(9):690-6. PubMed ID: 17919349
[TBL] [Abstract][Full Text] [Related]
13. The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer.
Dang C; Fornier M; Sugarman S; Troso-Sandoval T; Lake D; D'Andrea G; Seidman A; Sklarin N; Dickler M; Currie V; Gilewski T; Moynahan ME; Drullinsky P; Robson M; Wasserheit-Leiblich C; Mills N; Steingart R; Panageas K; Norton L; Hudis C
J Clin Oncol; 2008 Mar; 26(8):1216-22. PubMed ID: 18323546
[TBL] [Abstract][Full Text] [Related]
14. Cardiac toxicity of trastuzumab: experience at the Ghent Unversity Hospital, Belgium.
Lamot C; Rottey S; De Backer T; Van Bortel L; Robays H; Van Belle S; Denys H; Cocquyt V
Acta Clin Belg; 2010; 65(5):300-4. PubMed ID: 21128555
[TBL] [Abstract][Full Text] [Related]
15. High efficacy of pre-operative trastuzumab combined with paclitaxel following doxorubicin & cyclophosphamide in operable breast cancer.
Paluch-Shimon S; Wolf I; Goldberg H; Evron E; Papa MZ; Shabtai M; Barsuk D; Yosepovich A; Modiano T; Catane R; Kaufman B
Acta Oncol; 2008; 47(8):1564-9. PubMed ID: 18607846
[TBL] [Abstract][Full Text] [Related]
16. First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial.
Untch M; Muscholl M; Tjulandin S; Jonat W; Meerpohl HG; Lichinitser M; Manikhas AG; Coumbos A; Kreienberg R; du Bois A; Harbeck N; Jackisch C; Müller V; Pauschinger M; Thomssen C; Lehle M; Catalani O; Lück HJ
J Clin Oncol; 2010 Mar; 28(9):1473-80. PubMed ID: 20177030
[TBL] [Abstract][Full Text] [Related]
17. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial.
Suter TM; Procter M; van Veldhuisen DJ; Muscholl M; Bergh J; Carlomagno C; Perren T; Passalacqua R; Bighin C; Klijn JG; Ageev FT; Hitre E; Groetz J; Iwata H; Knap M; Gnant M; Muehlbauer S; Spence A; Gelber RD; Piccart-Gebhart MJ
J Clin Oncol; 2007 Sep; 25(25):3859-65. PubMed ID: 17646669
[TBL] [Abstract][Full Text] [Related]
18. [Update: adjuvant trastuzumab in HER2 positive breast cancer].
Tahover E; Sonnenblick A; Peretz T; Katz D
Harefuah; 2012 Jan; 151(1):37-42, 61. PubMed ID: 22670500
[TBL] [Abstract][Full Text] [Related]
19. Pegylated liposomal doxorubicin and trastuzumab as 1st and 2nd line therapy in her2/neu positive metastatic breast cancer: a multicenter phase II trial.
Stickeler E; Klar M; Watermann D; Geibel A; Földi M; Hasenburg A; Gitsch G
Breast Cancer Res Treat; 2009 Oct; 117(3):591-8. PubMed ID: 19156515
[TBL] [Abstract][Full Text] [Related]
20. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment.
Ewer MS; Vooletich MT; Durand JB; Woods ML; Davis JR; Valero V; Lenihan DJ
J Clin Oncol; 2005 Nov; 23(31):7820-6. PubMed ID: 16258084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]